GlobeNewswire by notified

Amolyt Pharma Announces Research Agreement and Licensing Option with XOMA


Amolyt to advance pre-clinical development of anti-PTHR1 monoclonal antibodies as potential treatments of primary hyperparathyroidism (PHPT) and humoral hypercalcemia of malignancy (HHM)

Amolyt has obtained the option to license one or more candidates from XOMA for further clinical development worldwide

PHPT and HHM are rare endocrine diseases with high unmet needs and these candidates from XOMA represent a natural expansion of Amolyt’s current development pipeline

LYON, France and CAMBRIDGE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Amolyt Pharma (“Amolyt,” “Amolyt Pharma” or the “Company”), a global company specialized in developing innovative therapies for rare endocrine and related diseases, today announced that the Company has entered into a research agreement and licensing option with XOMA Corporation (“XOMA”) for the pre-clinical evaluation of a select set of monoclonal antibodies that arose from XOMA’s legacy discovery efforts as potential treatments for primary hyperparathyroidism (“PHPT”) and humoral hypercalcemia of malignancy (“HHM”). Amolyt has the option to license one or more of these candidates from XOMA for further clinical development worldwide.

Both PHPT and HHM are rare endocrine diseases with high unmet needs and a common target, the parathyroid hormone 1 receptor (“PTHR1”), and are characterized by the hypersecretion of parathyroid hormone (“PTH”) and parathyroid hormone-related peptide (“PTHrP”), respectively, resulting in continuous stimulation of the PTHR1, leading to bone loss, hypercalcemia and hypophosphatemia. The objective of the research agreement is to test the anti-PTHR1 antibodies in relevant animal disease models with the aim of selecting a candidate that can successfully halt the over-stimulation of the PTHR1 caused by excess PTH and PTHrP and eliminate the debilitating symptoms and serious complications associated with PHPT and HHM.

“We are continuing to build our portfolio for rare endocrine and related diseases while moving, in parallel, our lead program for hypoparathyroidism into a pivotal trial. This new program for primary hyperparathyroidism and humoral hypercalcemia of malignancy represents a natural expansion of our pipeline and leverages our clinical expertise in the field of calcium and bone metabolism and in the biology of parathyroid hormone and its receptor,” stated Thierry Abribat, Ph.D., chief executive officer of Amolyt Pharma.

“We look forward to advancing this pre-clinical work and, if successful, entering into a license agreement with XOMA in order to bring the program to patients, to expand our development pipeline and to establish more opportunities for long-term value creation,” Dr. Abribat concluded.

Brad Sitko, chief investment officer of XOMA, added, “Given Amolyt’s established expertise in rare endocrine disorders, and specifically diseases stemming from dysregulation of PTH, we believe they are a great partner to advance the development of these promising antibodies. We look forward to watching Amolyt’s progress, as PHPT and HHM patients are underserved by current standards of care.”  

About Primary Hyperparathyroidism (“PHPT”)
Primary hyperparathyroidism involves excessive PTH production due to enlargement of one or more of the parathyroid glands located at the front and base of the neck that leads to hypercalcemia. Excess serum calcium affects multiple body systems including the skeletal, gastrointestinal, renal (kidney), muscular, cardiovascular, and central nervous systems. Most commonly, primary hyperparathyroidism is seen in people over 60 years of age and is more common in women. Radiation to the head and neck increases the risk of developing the disease as does rare parathyroid carcinoma. In approximately 85% of cases, PHPT is caused by a single adenoma. In approximately 15% of cases, multiple glands are involved (either multiple adenomas or hyperplasia) and management of the disease is more challenging. Prevalence is estimated at ~233/100k women and 85/100k men.

About Humoral Hypercalcemia of Malignancy (“HHM”)
Approximately 20% of all cancer patients develop hypercalcemia during their clinical course, and 80% of those cases are caused by excessive secretion of PTHrP from tumor cells (HHM). Squamous cell carcinomas of the head, neck, esophagus and lung, and cancers of the cervix, lung and colon are most commonly involved, in addition to renal cell, bladder, breast, endometrial, and ovarian cancers. It is associated with a wide spectrum of symptoms including nausea, vomiting, anorexia, abdominal pain, constipation, polyuria, hypotension, bone pain, bone loss fatigue and confusion. Renal failure or coma can occur; thus, this condition may be considered an oncologic emergency. Current standard of care is focused on bone anti-resorptive therapy, and intravenous hydration to enhance urinary calcium excretion. However there are many limitations to available therapy and unwanted effects include fever, bone pain, renal toxicity, hypocalcemia, and osteonecrosis of the maxilla and mandible. A better tolerated systemic therapy that directly targets the interaction between PTHrP and the PTHR1, rather than the downstream effect on bone resorption, has the potential to provide a safer, more effective alternative. Based on a prevalence study in the United States, HHM represented about 57,000 cases in 2013.

About Amolyt Pharma
Amolyt Pharma, a clinical stage biotechnology company, is building on its team’s established expertise to deliver life-changing treatments to patients suffering from rare endocrine and related diseases. Its development portfolio includes eneboparatide (AZP-3601), a long-acting PTH1 receptor agonist as a potential treatment for hypoparathyroidism, and AZP-3813, a peptide growth hormone receptor antagonist for the potential treatment of acromegaly. Amolyt Pharma aims to further expand and develop its portfolio by leveraging its global network in the field of endocrinology and with support from a strong syndicate of international investors. To learn more, visit or follow us on Twitter and LinkedIn.

Media inquiries:
Jordyn Temperato
LifeSci Communications

Investor inquiries:
Ashley Robinson
LifeSci Advisors, LLC

To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Online Retailer Das Kostümland Deploys Descartes’ Ecommerce Warehouse Management Solution to Strengthen Peak Season Fulfillment6.2.2023 12:45:00 CET | Press release

MUNICH, Germany and ATLANTA, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Descartes Systems Group (Nasdaq: DSGX) (TSX: DSG), the global leader in uniting logistics-intensive businesses in commerce, announced that Das Kostümland, a leading German vendor of costumes and disguises, has deployed Descartes’ ecommerce warehouse management system (WMS) to keep pace with dramatic order volume seasonal spikes. The Descartes solution streamlines and accelerates the retailer’s fulfillment processes, increasing operational efficiency, reducing costs, and enhancing the customer experience. “We have more than 10,000 SKUs and, during seasonal peaks such as Halloween, we process upwards of 2,000 orders per day,” said Daria May, founder and CEO of Das Kostümland. “With Descartes’ barcode-based pick and pack processes, we’ve increased our warehouse productivity to handle even extreme seasonal order fluctuations without hiring additional labor. By optimizing our fulfillment processes, we’ve reduced picking errors,

Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression6.2.2023 12:30:00 CET | Press release

Zuranolone is being evaluated as a potential 14-day, rapid-acting, once-daily, oral medication to treat major depressive disorder (MDD) and postpartum depression (PPD) Depression is a public health issue with significant unmet medical need CAMBRIDGE, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics, Inc. (Nasdaq: SAGE) announced the U.S. Food and Drug Administration (FDA) has accepted the filing of a New Drug Application (NDA) for zuranolone in the treatment of major depressive disorder (MDD) and postpartum depression (PPD). Zuranolone is an investigational drug being evaluated as a 14-day, rapid-acting, once-daily, oral treatment in adults with MDD and PPD. The application has been granted priority review and the FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of August 5, 2023. “We see potential for zuranolone, if approved, to be a meaningful new option that can help address the serious unmet need faced by the diverse pop

Maha Energy enters into a definitive agreement regarding the business combination with DBO 2.0 S.A.6.2.2023 12:05:00 CET | Press release

Maha Energy AB (publ) (“Maha” or the ”Company”) is pleased to announce that it has signed the definitive agreement with the shareholders of DBO 2.0 S.A. (“DBO”), with respect to the previously announced (on December 5, 2022) business combination, which involves (i) a maximum issuance of 36,775,410 new shares in Maha, to be subscribed by DBO’s shareholders as a consideration; and (ii) the transfer of DBO’s existing shares to Maha by DBO’s shareholders (“Transaction”). The Transaction is subject to customary conditions precedent, including an Extraordinary General Meeting in Maha approving the necessary resolutions. The Transaction is expected to close in the 1st half of 2023. Founded in 2017, DBO is a private upstream oil and gas company that focus on mature offshore fields in Brazil. It has attracted North Sea investors to invest in Brazilian assets, working with Brazilian partners, and applying the most advanced Northern Sea techniques in order to: (1) identify additional reserves, (2

Maha Energy sluter slutgiltigt avtal avseende sammanslagning av verksamheterna med DBO 2.0 S.A.6.2.2023 12:05:00 CET | Pressemelding

Maha Energy AB (publ) (“Maha” eller ”Bolaget”) meddelar härmed att Bolaget har slutit ett slutgiltigt avtal med aktieägarna till DBO 2.0 S.A. (”DBO”) avseende den tidigare överenskomna och den 5 december 2022 offentliggjorda sammanslagning av verksamheterna, vilken inkluderar (i) en köpeskilling om maximalt 36 775 410 nyemitterade aktier i Maha som tecknas av DBOs aktieägare,: och (ii) att aktieägarna i DBO överför aktierna i DBO till Maha (”Transaktionen”). Transaktionen är villkorad sedvanliga förbehåll, inklusive en extra bolagsstämma i Maha för att fatta de nödvändiga besluten. Transaktionen beräknas kunna slutföras under första halvåret 2023. DBO är ett privat upstream olje- och gasbolag med fokus på mogna offshorefält i Brasilien. DBO grundades 2017 och har attraherat Nordsjöinvesterare att investera i brasilianska tillgångar, arbeta med brasilianska partners och tillämpa de mest avancerade teknikerna från Nordsjön för att (1) identifiera ytterligare reserver, (2) utveckla mogna

Scandinavian Tobacco Group A/S: Transactions in connection with share buy-back programme6.2.2023 11:59:00 CET | Press release

Company Announcement No. 6/2023 Copenhagen, 6 February 2023 Transactions in connection with share buy-back programme On 19 May 2022, Scandinavian Tobacco Group A/S announced that the share buy-back programme that was initiated 9 March 2022 was increased to an aggregated value of up to DKK 1,000 million. The purpose of the programme is to adjust the Company’s capital structure and meet obligations relating to the Group’s share-based incentive programme. Part of the buy-back programme is executed in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (the “Market Abuse Regulation”) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. Another part of the share buy-back programme is conducted as a directed buy-back from Chr. Augustinus Fabrikker Aktieselskab and C.W. Obel A/S as further described in company announcement no. 35/2022. The share buy-back programme will end no later than 28 February 2023. Th